# Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

> **NCT00243594** · PHASE1,PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Melanoma Stage III or IV

## Interventions

- **BIOLOGICAL:** Peptide-pulsed dendritic cells

## Key facts

- **NCT ID:** NCT00243594
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2009-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243594, "Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00243594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*